--- title: 'Clinical Daily Summary: What Happened on November 5, 2026' headline: BioNTech raises revenue outlook amid mixed cancer-trial results description: UK industry-trial enrollment fell for a fifth year. Intellia completed enrollment in a gene-editing study, and Tango and Erasca opened a cancer-combination trial. url: https://thebench.bio/news/clinical/2026-11-05 topic: clinical date: '2026-11-05' covers: - '2026-11-05' date_published: '2026-11-05T12:09:58Z' date_modified: '2026-11-05T12:09:58Z' tags: - Clinical - Industry sources: 4 publisher: TheBench.Bio --- # Clinical Daily Summary: What Happened on November 5, 2026 **BioNTech raises revenue outlook amid mixed cancer-trial results** UK industry-trial enrollment fell for a fifth year. Intellia completed enrollment in a gene-editing study, and Tango and Erasca opened a cancer-combination trial. ## Today in brief BioNTech raised its 2026 revenue outlook and reported mixed results across its cancer pipeline. [1] Gotistobart showed a survival benefit in an initial analysis, while BNT113 missed a progression-free-survival endpoint and a colorectal cancer vaccine trial will stop early. [1] UK enrollment in industry-sponsored clinical trials fell for a fifth consecutive year, to 17,618 NHS participants in 2025/26. [2] Intellia completed enrollment in a Phase 3 gene-editing trial for hereditary transthyretin amyloidosis with polyneuropathy. [3] Tango Therapeutics and Erasca began enrolling patients in a Phase 1/2 trial combining two drugs for selected lung and pancreatic cancers. [4] ## BioNTech’s cancer pipeline posts gains and setbacks BioNTech raised its 2026 revenue outlook to €1.7 billion–€1.9 billion, from a previous range of €1.6 billion–€1.9 billion. [1] Third-quarter revenue was €1.289 billion, including €613 million from its Bristol Myers Squibb collaboration and €554 million from COVID-19 vaccines. [1] In the non-pivotal portion of a Phase 3 trial, gotistobart improved overall survival versus chemotherapy. BioNTech said median survival was nearly twice as long. [1] BioNTech expects interim results from the trial’s second portion before the end of 2026, after review by an independent monitoring committee. [1] The Phase 3 DYNASTY-Breast02 trial of trastuzumab pamirtecan met its primary endpoint, progression-free survival. BioNTech described the effect as moderate and reported more interstitial lung disease, including severe and fatal cases. [1] BioNTech and partner DualityBio are reviewing breast and uterine cancer data before deciding next steps, leaving a previously anticipated regulatory filing uncertain. [1] BNT113 did not significantly improve progression-free survival when added to pembrolizumab, compared with pembrolizumab alone, in the AHEAD-MERIT trial. [1] BioNTech will continue assessing overall survival. A separate Phase 2 trial of autogene cevumeran after colorectal cancer surgery and chemotherapy is being stopped early. [1] A Phase 2 autogene cevumeran trial in pancreatic cancer continues, with recruitment completed in August. [1] ## UK industry-trial recruitment falls for a fifth year The UK recorded 17,618 NHS participants in industry clinical trials in 2025/26, down from 19,507 the year before and 31% below 2022/23. [2] Industry-sponsored studies accounted for 3.8% of interventional-trial participants, compared with a share that had consistently exceeded 10% before the pandemic. [2] The Association of the British Pharmaceutical Industry said trial initiations had improved, but the UK ranked seventh for Phase 1 and Phase 3 starts and fifth for Phase 2 in 2025/26. [2] Every study received an approval decision within 60 days in August 2026. But only 35% of studies opened to patients within 60 days of approval during 2025/26, against a 90% target. [2] The report called for a UK-wide NHS data service to identify potential participants and more funding for trial delivery. [2] ## Intellia completes enrollment in hereditary amyloidosis trial Intellia completed enrollment of about 60 adults in MAGNITUDE-2, a randomized Phase 3 trial of nexiguran ziclumeran for hereditary transthyretin amyloidosis with polyneuropathy. [3] The treatment uses in vivo CRISPR gene editing to disable TTR in liver cells, reducing production of transthyretin protein. [3] The trial compares a single infusion with placebo. It will assess changes in blood TTR at day 29 and neuropathy impairment at month 18. [3] Intellia is also studying the treatment in a separate Phase 3 trial for transthyretin amyloidosis with cardiomyopathy. [3] ## Tango and Erasca start combination-trial enrollment Tango Therapeutics and Erasca opened enrollment in a Phase 1/2 study of ERAS-0015 plus vopimetostat for selected pancreatic and lung cancers. [4] The open-label trial will test escalating doses to determine the combination’s maximum tolerated dose. It will also assess safety, drug exposure and antitumor activity. [4] ERAS-0015 is an oral pan-RAS inhibitor, while vopimetostat blocks PRMT5, a protein involved in cell growth. [4] Erasca has reported partial responses at dose levels starting at 8 mg once daily in an early dose-escalation study of ERAS-0015 alone. [4] ## The day in numbers - **€1.7 billion–€1.9 billion**: BioNTech’s updated 2026 revenue outlook [1] - **17,618**: NHS participants in UK industry clinical trials in 2025/26 [2] - **35%**: UK studies opened to patients within 60 days of approval, against a 90% target [2] - **About 60**: Adults enrolled in Intellia’s MAGNITUDE-2 trial [3] ## Also published - [STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug](), STAT Biotech - [How Testing Tumors After Recurrence be Improved](), Pharmaceutical Executive - [Podcast: An investor’s guide to preparing your clinical data package](), Clinical Trials Arena - [Addressing the rheumatic disease diagnostic gap in primary care](), Pharmafile - [De-Risking FIH: Integrated Strategies for Rapid Proof-of-Concept (Sept 2026)](), Applied Clinical Trials - [Quotient Sciences first-in-human to proof-of-concept studies](), Applied Clinical Trials - [Why the best CROs challenge the trial plan and keep challenging it](), pharmaphorum - [The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time](), Applied Clinical Trials - [How to recruit specialty volunteer populations for eary-phase clinical research: 5 things to ask when choosing a CRO partner (Sept 2026)](), Applied Clinical Trials ## Sources 1. [BioNTech: BMS becomes a revenue mainstay — but the pipeline still has to deliver](), European Biotechnology, 2026-11-05 2. [“Urgent action” needed as UK trial recruitment falls again](), Clinical Trials Arena, 2026-11-05 3. [Intellia concludes Phase III ATTRv-PN study enrolment](), Clinical Trials Arena, 2026-11-05 4. [Tango and Erasca’s Phase I/II trial of ERAS-0015 combo opens for enrolment](), Clinical Trials Arena, 2026-11-05 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: